About the Study

B-cell acute lymphoblastic leukemia (B-ALL): A study on cell therapy medication to treat cancer cells and prevent relapse

This study is for individuals between 1 year of age and 25 years of age who have been diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). It involves children or young adults who have recently started receiving cancer treatment for the first time and have a small number of cancer cells still detected in their bodies after the first part of treatment. When these small number of cancer cells are present after the induction and consolidation treatment phases (initial months of treatment) for B-ALL, the patients are considered to be in a high risk group. This means their cancer is harder to treat and may be more likely to return after treatment. The goal of this study is to see if a specific type of cell therapy medication may treat the remaining small amount of cancer cells and help prevent relapse in children and young adults who are part of this high-risk group.

Interested in learning more?

Full Study Name: A cellular therapy study for recently-diagnosed B-cell acute lymphoblastic leukemia (B-ALL) patients who have a small amount of cancer cells still present in their bodies following the initial months of treatment